22/09/2026
Ebola Outbreak 2026: Why Early Detection Matters
The 2026 Bundibugyo virus disease outbreak in the Democratic Republic of the Congo continues to highlight the importance of timely case detection and diagnostic capacity.
According to the latest WHO update, as of 7 September 2026, the outbreak had resulted in 6,757 confirmed cases and 3,267 deaths across 61 health zones in the DRC.
In rapidly evolving outbreaks, diagnostic tools need to support healthcare teams where testing is needed — including primary healthcare facilities, community settings, and field laboratories.
The Accu-Tell® Ebola Virus Antigen Cassette (Whole Blood/Serum/Plasma) is a rapid lateral flow immunoassay for the qualitative detection of Ebola virus antigens.
Key features include:
• Whole blood, serum and plasma specimens
• Fingerstick whole blood option for point-of-care use
• Results available within 15–20 minutes
• Lateral flow immunoassay format
• Designed for professional IVD use
• Suitable for community settings, primary healthcare facilities and field laboratories
Rapid testing is not a replacement for confirmatory molecular testing.
Instead, it can be part of a broader diagnostic workflow that supports timely identification and further evaluation of suspected cases.
Rapid Screening. Practical Testing. Supporting Timely Response.
AccuBioTech — Reliable Solutions for Rapid Diagnostics.